Meet Alexander Schuth, M.D., the Chief Operating and Financial Officer of Denali Therapeutics. He joined Denali in 2015 and has a solid track record in the biotech world, being a key player since the company was founded. Before that, he...

Current Market Cap

$3.47B

Number of Employees

375

Total Compensation

2022 - 2022

Trending up by 0.00% last year
Showing total compensation for the last 2022 - 2022

Stock

Up by 0.00% last year

Salary

Up by 0.00% last year

Bonus

Up by 0.00% last year

Other

Up by 0.00% last year

Year

2022

Total Compensation

$737.20K

Salary

$500.00K

Board Justification

The compensation philosophy focuses on pay for performance, aligning executive compensation with the achievement of strategic business goals and shareholder interests.

Bonus

$225.00K

Board Justification

The annual bonus was based on the achievement of corporate goals, with a funding percentage of 100% of target due to meeting 75% of the goals set for 2022.

Other

$12.20K

Board Justification

Other compensation includes employer 401(k) matching contributions.

Restricted Stock

$0.00(0 RSU)

Board Justification

No stock was vested in 2022 as the focus was on options and RSUs granted in previous years.

Performance Metrics

The performance metrics included achieving corporate goals related to product development and strategic initiatives.

SEC Filing

From April 18, 2023

Alexander Schuth, M.D.

CEO of Denali Therapeutics Inc.

D

Education

Field of Expertise

Born

Invalid Date - 0 years ago

Is Founder?

No

Current Tenure

2 years 6 months (May 2022 - Present)

Previous Experience

Unknown

View Holdings

Insider Holdings of Alexander Schuth, M.D.

DNLI

$20.30M

$6.52M (47.36%)

Last Insider Trade

DNLI

$63.11K

DNLI at $24.78/share

Aug 20, 2024

Sale